Health care to get dramatically worse ?

Great letters to the editor in the NYT (Jan 6).  In particular, Dr. Nikhil Singh (Nephrology Fellow at Yale) “…full repeal of this law [ACA] will kill people”.  As a physician with 35 years taking care of cancer patients in 2 different states and several different hospitals, I fully concur.  And Kenneth Raske (Pres. Greater New York Hospital Association) writes: “In New York State…27 hospitals are on the watch list for financial vulnerability…and many more are in fiscal distress.  [Full] repeal of the ACA…will make things dramatically worse”.  Hey Suffolk county, that includes our hospitals and our health care!

 

Posted in ACA | Comments Off on Health care to get dramatically worse ?

No to Medicare Privatization

medicare_card

Letter to the Editor by Mike Anthony – published in the Southampton Press

Since the November 8th election, the focus has been placed on public policy options in a fully Republican-dominated federal government. One of those policy areas is Medicare and the direction US House Speaker Paul Ryan would like to take the program under his “Better Way” proposals; specifically, he is interested in privatizing Medicare and using a premium support stipend directed to beneficiaries to purchase their own health insurance in the marketplace.

There is a lot to chew over regarding that proposal, but as a former teaching hospital administrator, I would like to share my concerns solely related to Medicare’s role in teaching the future physicians of America.

Medicare is critical to teaching and training physicians – will that role be jeopardized under a privatization scheme?

Medicare supports nearly a quarter of all direct medical education costs (DGME) associated with training physicians: annual costs are $13 billion of which Medicare directly supports with $3 billion in payments to teaching hospitals. These payments help pay for stipends and fringe benefits, salary for supervision, administrative and overhead costs. (Note: Medicaid also supports medical education costs.)

In addition to the direct costs associated with training our future doctors, Medicare recognizes and pays for indirect costs associated with treating an older Medicare-eligible population that are common in teaching hospitals. Accordingly, Medicare provides an additional add-on called the Indirect Medical Education (IME) payment. Through this IME adjustment, teaching hospitals receive an additional $6.5 billion annually. What is critical to understand is that private insurance companies rarely recognize these additional costs in their reimbursements.

Since New York State has a robust physician training program, and many world-renown teaching hospitals, any diminution of teaching support payments from Medicare (and Medicaid) might place at risk the teaching mission at these hospitals.

For this and other reasons, we need to strengthen and not privatise Medicare.

A key aspect of Medicare: funding medical education.  Every physician has benefited!  Including myself.  David

Posted in Health Care | Tagged , , , | Comments Off on No to Medicare Privatization

Beware of deregulation in drug development

Beware of deregulation in drug development

Thalidomide baby

The 21st Century Cures Act passed congress on Dec. 7th and was signed into law on Dec 13th by President Obama.  This is a huge bill with something in it for everyone, and lots to criticize. As a retired researcher who spent nearly 40 years of my life writing research grants mostly to the National Institutes of Health (NIH), I applaud the long overdue increase in funding for the NIH. Funding had steadily decreased in an alarming fashion since sequestration in 2013.  Inflation adjusted loss of funding for the NIH reached 22% in a 2 year period: 2013-15.  But now there is a chance to catch up for these losses, in part because of The 21st Century Cures Act.  It is well documented that reduced federal funding leads to fewer grants, fewer new discoveries and a loss of talented scientists.  I have seen this first hand.  Research scientists and patient advocate groups welcome the prospect of more funding.

However, there is an ugly underbelly to the 21st Century Cures Act.  Perhaps not so well appreciated is the further erosion of the power of the FDA in keeping us safe from drugs that can be harmful, or that are just ineffectual.  It took lots of courage for a young FDA scientist in 1960 to stand up to the powerful drug industry trying to promote a poorly researched drug named thalidomide.  Frances Oldham Kelsey was the FDA scientist who kept thalidomide off the U.S. market and blocked approval for 19 months, thus saving thousands of babies from being born with severe deformities in the US.  In other countries, without a strong FDA, sales and marketing for pregnancy-associated nausea remained unchecked and tens of thousands of severely deformed babies were born resulting in untold suffering across the globe.

In the name of accelerating drug development, the FDA’s authority and the lengthy process of FDA approval have steadily been eroded over the last few decades and the 21st Century Cures Act could come as a fatal blow, especially with a new government bent on deregulating.  Lobbyists from the pharmaceutical and medical device industries and allied patient advocacy organizations are touting predicted miracle breakthroughs based on the law’s aim to weaken regulations and promote rapid drug development.  Most egregious is the use of anecdotal clinical experience as evidence that drugs are safe and effective; allowing antibiotics on the market based on pre-clinical evidence, that is, laboratory or animal studies, with little testing in humans; weakening the already limited evidence needed to approve medical devices (for example a stent for a coronary artery).  Similar concerns have been voiced in several leading medical and science publications (New England Journal of Medicine, JAMA, Science and Nature).

As stated by Michael Carome (Director, Health Research Group, at Public Citizen)  in the LA Times, “If universal praise for a measure makes your B.S. detectors twitch, you’re on the right track. The 21st Century Cures Act is a huge deregulatory giveaway to the pharmaceutical and medical device industry, papered over by new funding for those research initiatives”.  Nothing in this act addresses the main problem the public sees with the drug industry: unaffordable prices.   As stated by Elizabeth Warren “When American voters say Congress is owned by big companies, this bill is exactly what they are talking about”.

Consider Merck’s Vioxx, a painkiller and arthritis drug that the FDA approved in 1999. Vioxx was taken off the market in 2004 after it was shown to raise the risk of heart attacks. By then, 88,000 Americans had heart attacks while taking Vioxx, 38,000 of them fatal.

Personally, I will be a lot more averse to taking a new medication that has not stood the test of time!  And this is what I would recommend to my patients.

David Posnett MD

Sources:

1)    http://faseb.org/Science-Policy-and-Advocacy/Federal-Funding-Data/NIH-Research-Funding-Trends.aspx

2)    https://www.congress.gov/bill/114th-congress/house-bill/6

3)    Mike Debonis, Washington Post https://www.washingtonpost.com/news/powerpost/wp/2016/12/07/congress-passes-21st-century-cures-act-boosting-research-and-easing-drug-approvals/

4)    Michael Hiltzik, LA Times: http://www.latimes.com/business/hiltzik/la-fi-hiltzik-21st-century-20161205-story.html

5)   Gregg Gonsalves et al. The Hill   http://thehill.com/blogs/congress-blog/healthcare/307020-lawmakers-must-ask-tough-questions-about-the-21st-century

6)  Dark Remedy by Trent Stephens

Posted in Health Care | Comments Off on Beware of deregulation in drug development

Beware of deregulation in drug development

The 21st Century Cures Act passed congress on Dec. 7th and was signed into law on Dec 13th by President Obama.  This is a huge bill with something in it for everyone, and lots to criticize. As a retired researcher who spent nearly 40 years of my life writing research grants mostly to the National Institutes of Health (NIH), I applaud the long overdue increase in funding for the NIH. Funding had steadily decreased in an alarming fashion since sequestration in 2013.  Inflation adjusted loss of funding for the NIH reached 22% in a 2 year period: 2013-15.  But now there is a chance to catch up for these losses, in part because of The 21st Century Cures Act.  It is well documented that reduced federal funding leads to fewer grants, fewer new discoveries and a loss of talented scientists.  I have seen this first hand.  Research scientists and patient advocate groups welcome the prospect of more funding.

However, there is an ugly underbelly to the 21st Century Cures Act.  Perhaps not so well appreciated is the further erosion of the power of the FDA in keeping us safe from drugs that can be harmful, or that are just ineffectual.  It took lots of courage for a young FDA scientist in 1960 to stand up to the powerful drug industry trying to promote a poorly researched drug named thalidomide.  Frances Oldham Kelsey was the FDA scientist who kept thalidomide off the U.S. market and blocked approval for 19 months, thus saving thousands of babies from being born with severe deformities in the US.  In other countries, without a strong FDA, sales and marketing for pregnancy-associated nausea remained unchecked and tens of thousands of severely deformed babies were born resulting in untold suffering across the globe.

In the name of accelerating drug development, the FDA’s authority and the lengthy process of FDA approval have steadily been eroded over the last few decades and the 21st Century Cures Act could come as a fatal blow, especially with a new government bent on deregulating.  Lobbyists from the pharmaceutical and medical device industries and allied patient advocacy organizations are touting predicted miracle breakthroughs based on the law’s aim to weaken regulations and promote rapid drug development.  Most egregious is the use of anecdotal clinical experience as evidence that drugs are safe and effective; allowing antibiotics on the market based on pre-clinical evidence, that is, laboratory or animal studies, with little testing in humans; weakening the already limited evidence needed to approve medical devices (for example a stent for a coronary artery).  Similar concerns have been voiced in several leading medical and science publications (New England Journal of Medicine, JAMA, Science and Nature).

As stated by Michael Carome (Director, Health Research Group, at Public Citizen)  in the LA Times, “If universal praise for a measure makes your B.S. detectors twitch, you’re on the right track. The 21st Century Cures Act is a huge deregulatory giveaway to the pharmaceutical and medical device industry, papered over by new funding for those research initiatives”.  Nothing in this act addresses the main problem the public sees with the drug industry: unaffordable prices.   As stated by Elizabeth Warren “When American voters say Congress is owned by big companies, this bill is exactly what they are talking about”.

Consider Merck’s Vioxx, a painkiller and arthritis drug that the FDA approved in 1999. Vioxx was taken off the market in 2004 after it was shown to raise the risk of heart attacks. By then, 88,000 Americans had heart attacks from taking Vioxx, 38,000 of them fatal.

Personally, I will be a lot more averse to taking a new medication that has not stood the test of time!  And this is what I would recommend to my patients.

David Posnett MD

Sources:

1)    http://faseb.org/Science-Policy-and-Advocacy/Federal-Funding-Data/NIH-Research-Funding-Trends.aspx

2)    https://www.congress.gov/bill/114th-congress/house-bill/6

3)    Mike Debonis, Washington Post https://www.washingtonpost.com/news/powerpost/wp/2016/12/07/congress-passes-21st-century-cures-act-boosting-research-and-easing-drug-approvals/

4)    Michael Hiltzik, LA Times: http://www.latimes.com/business/hiltzik/la-fi-hiltzik-21st-century-20161205-story.html

5)   Gregg Gonsalves et al. The Hill   http://thehill.com/blogs/congress-blog/healthcare/307020-lawmakers-must-ask-tough-questions-about-the-21st-century

6)  Dark Remedy by Trent Stephens

Posted in Health Care | 2 Comments

Social Security ‘Reform’

Reprinted from The East Hampton Star

http://easthamptonstar.com/Letters-Editor/20161222/Letters-Editor-122216

12/22/2016

Dear David:

None of us should forget that Donald Trump campaigned very loudly on an explicit promise not to touch anyone’s Social Security benefits. Unfortunately, and with tens of millions of recipients’ benefits now under attack, we will learn whether this promise, like so many others he barked over the last 18 months, is destined to the dustbin of history.

Without any public explanation, especially curious in light of Mr. Trump’s unambiguous promise, Congressman Sam Johnson (R-Texas), the chairman of the subcommittee on Social Security of the powerful House Ways and Means Committee, has introduced another G.O.P. proposal (H.R 6489) to “reform” (read “hollow out all benefit levels”) Social Security, to be taken up when Congress meets next year. Disingenuously described as a method to “permanently save” Social Security, Johnson’s idea of “reform” is to slash nearly everyone’s benefits rather than devise a means to fund the program into the future.

So what would his plan do? According to an analysis prepared by a journalist with Mother Jones (based upon a report by a Social Security actuary), if a recipient has spent his or her life below the poverty level (an annual income of $12,000 or less) Representative Johnson’s plan would bump benefits by 22 percent. Sounds nice, right? Here’s the kicker: people making between $22,000 and $49,000 annually over their lifetimes would see their benefits slashed, up to 28 percent.

It gets worse. Workers having lifetimes average incomes between $49,000 and $78,000 would on average see a 33 percent cut, and those with average annual incomes between $78,000 and $118,000 would suffer an average 43 percent cut, with some benefits cut as much as 70 percent.

Congressman Johnson’s plan doesn’t even pretend to be friendly to middle-class earners. (Remember Trump’s promise to fight for them.) Instead, it treats the long-term health of Social Security as the paramount goal. Because increasing the program’s revenue is anathema to the G.O.P., the only way to achieve that goal is to dramatically reduce its benefits (and the program’s underlying purpose) through deep and broad benefit cuts. For those of you for whom this is a concern, while you may not be able to afford to retire, you can rest comfortably knowing that the Social Security program may be solvent.

As usual with these plans, a lot of its provisions are phased in gradually over time. But some of them kick in right away; even people who are already retired would suffer benefit cuts. As an example, Johnson’s plan reduces the annual cost-of-living increase — and eliminates it entirely for anyone with past earnings over $85,000 — beginning in 2018.

The incoming G.O.P. establishment has already put Medicare and Medicaid on the chopping block. Now, quietly, Social Security has a target on its back. The unbounded cruelty of the G.O.P. elected leaders toward those they serve, namely us, should not be countenanced.

Sincerely,

BRUCE COLBATH

Posted in Uncategorized | Comments Off on Social Security ‘Reform’

Future Cost of Medical Care

Reprinted from The East Hampton Star 12/22/2016

http://easthamptonstar.com/Letters-Editor/20161222/Letters-Editor-122216

 

Cost of a New Knee

To the Editor:

How much will my metal knee cost?

One of us is considering a total knee replacement. A titanium knee! So we did some research on cost (the below considerations are applicable to any surgical or medical treatment).

The average overall cost for a knee replacement in the United States is $30,000 to $45,000. The cost is about $40,000 at a hospital in New York City.

More than 400,000 Medicare beneficiaries had knee or hip replacement surgery in 2014, the Department of Health and Human Services reported.

Medicare Part A and Part B (also known as Original Medicare) cover different portions of this procedure and the associated aftercare. How much is covered by Medicare? And what does the patient have to pay?

To keep costs down for the government, Medicare has contracted with the hospital in New York City. Medicare pays a set price for the inpatient hospital portion; let’s estimate $8,000, leaving you to pay a pre-set deductible of $2,000, either from your savings or using a secondary health insurance, if you have one. This covers the Part A portion of Medicare; Part B will pay for physician services.

What about the hospital and the surgeon? Can they charge above the negotiated prices? They have little choice: They can absorb the losses or flatly refuse to take Medicare or Medicaid patients. When Medicare fixes their prices for a given procedure, the hospital and surgeon may not charge the difference between the posted charges and the Medicare reimbursement amount, and the physician accepts “assignment.” The Medicare program developed these payment systems because they realized that hospital charges rarely reflect the true cost of providing services.

The good news is that we found a hospital and a surgeon that will take on the case even though the patient is on Medicare.

Assuming Obamacare is repealed and Medicare is privatized in 2017, how is this going to change coverage for the planned surgery? The government is no longer a player. It is now just the provider (hospital and surgeon) vs. private insurance companies in a free-market system. Insurance companies will want to minimize their costs. They will a) bargain with providers, b) increase the deductible, co-pay, and co-insurance, paid by the patient, and c) increase the monthly patient premium insurance rates. There will be no incentive for providers to cut their costs and be less wasteful.

Obamacare provided those incentives, known as 1) Accountable Care Organizations, designed to coordinate care, and 2) transitioning from a fee-for-service model (paying on volume) to a bundled payment model (paying on disease episode). At the new bargaining table are only insurance companies and the hospital and surgeon. The patient has no representative at the table, since the government has pulled out. As every lawyer will tell you, without legal representation you are screwed.

The worst-case scenario is insurance companies increasing premium rates for everyone, because covering an elderly and sicker patient population without help from the government will greatly impact their risk pool.

It is difficult to model a payment scenario under a newly voucherized system where consumers are given a pre-set premium amount and told to go find the insurance that best suits their needs. We do know the following, though: With Obamacare repealed, insurance companies would no longer be obligated to use 80 percent of premium payments toward patient coverage.

With Obamacare care repealed, lifetime limits may apply. With Obamacare repealed, pre-existing exclusions may come back. With Medicare privatized, deductibles, co-insurance, and co-pays will no longer be set by Medicare, but by the needs of the insurance company.

Let’s make some assumptions. The hospital still offers the procedure for $40,000, and it has contracted with your selected, privatized Medicare insurance to do it for $20,000. However, that $20,000 will include a much higher deductible, co-pays, and co-insurance that will be the patient’s responsibility. So, whereas under traditional Medicare, in our example, the patient responsibility will be about $2,000, payments under a new privatized plan, unfortunately, will skyrocket — perhaps to $4,000 to $8,000?

DAVID N. POSNETT

Posted in Uncategorized | Comments Off on Future Cost of Medical Care

Ebola Vaccine Would Likely Have Been Found By Now If Not For Budget Cuts

Nice article quoting NIH director Francis Collins and outlining the dangers of vast budget cuts (by a Republican congress) and how that might have contributed to our poor preparedness for the current worldwide Ebola outbreak.  Having reviewed this topic and given a public talk on Ebola just one month ago, I fully agree.

It should be easy to develop a vaccine against Ebola and there are good projects under way.  But Ebola was never considered a threat to us in America (just a lingering threat for some poor African nations).  No companies want to bring a vaccine or a drug to market, when they don’t forecast profit.  It’s the story of orphan drugs and now orphan vaccines!  The story is compelling because it illustrates that the interests of private companies are not always aligned with the interests of the public.

For the most recent on Ebola, try this source.

NIH budget over the years

NIH budget over the years

Posted in Uncategorized | 3 Comments

Medicine for the One Percent

We always suspected this: a new study clearly shows that the richer you are, the longer you live in the US of America (Wall Street Journal). This is no small difference! The top 10% (richest) people live on average 10 years longer than the bottom 10% (poorest). Wow! And this is WITH medicare and medicaid, which the political right would have us get rid of all together.

What I would like to see are 2 things.

(1) A comparison with a similar study in civilized “1st world” countries (Canada, UK, Germany, France, Switzerland, Netherlands, etc.) with better health care coverage that covers the entire population.

(2) A historical comparison: an analysis of life expectancy relative to individual wealth 100 , 50, 20 and 10 years ago in the US. I would like to know whether we have made any progress, and whether (as I suspect) progress has been halted or even reversed.

It will take at least 10-50 years for the effects of Obamacare to show up in such a population wide analysis which measures death rates over many years. At present, only a comparison with other countries can tell us something.

Here is a partial response to my question (2) from the article itself which looks at least at 2 different historical time points: 1920 versus 1940.  For men there has been an improvement in longevity (5.9% for the richest men and 1.7% for the poorest men).  For women the change in longevity is 3.1% for the richest women.  But the poorest women actually live less long -2.1%.    This means that if you are a poor woman, you actually would have been better off being born in 1920  rather than in 1940!  That is a stunning fact.  It is the reverse of progress.

change in life expect

 

Posted in ACA, Health Care | Tagged , , , , , , | 2 Comments

Soaring Costs of Prescription Drugs in the US

Great article about the soaring costs of prescription drugs in the US.  The very same drugs are offered in other countries like Germany and the UK etc, at a small fraction of what we are asked to pay.  Who benefits?  The drug companies.  Since most countries have government limits on the costs of drugs, the drug companies make less of a profit in those countries (but still enough to continue selling there).  To make up for what they view as insufficient margins, they go crazy with the prices in the US, where there are no government limits.  The free market just doesn’t work when it comes to life saving medicines.  Unless you decide that only the lives of the rich are worth saving.

Posted in Health Care | Tagged , , , | 1 Comment

The ACA seems to be working…

Robert Reich discusses the ACA which seems to be working.  But there is a lot that needs fixing.  Above all what needs fixing is the oft deceitful misinformation.  Read on here!  Contributed by Arlene Coulter.

 

 

Posted in ACA, Health Care | Tagged , , , , , | Comments Off on The ACA seems to be working…